Docetaxel/ramucirumab in the second-line treatment of stage IV NSCLC

A randomised, double-blind, phase III REVEL study demonstrated a statistically significant improvement in overall response rate, progression-free survival, and overall survival for ramucirumab plus docetaxel vs. docetaxel in patients with stage IV non-small-cell lung cancer as a second-line treatment after platinum-based therapy. Benefits were similar in patients with non-squamous and squamous tumours and no unexpected adverse events were identified, according to a presentation by Dr Maurice Perol of the Léon-Bérard Cancer Centre, Lyon, France at American Society of Clinical Oncology 2014 Annual Meeting. Read more here.